Skip to main content

News

Biogen's stock could fall 10% on new Alzheimer's drug data this week, top analyst says

By CNBC  
   December 02, 2019

Biogen’s stock could fall as much as 10% once it releases new data this week on its Alzheimer’s drug, analyst Brian Skorney says. “We do not think that data validates anything near receiving approval from the FDA,” he adds.

Full story


Get the latest on healthcare leadership in your inbox.